Beruflich Dokumente
Kultur Dokumente
2011;60:191-203
DOI: 10.2332!
allergolint.11-RAI-0335
REVIEW ARTICLE
ABSTRACT
The definition, classification, pathogenesis, test methods, clinical findings, criteria for diagnosis, and therapies
of allergic conjunctival disease are summarized based on the Guidelines for Clinical Management of Allergic
Conjunctival Disease (Second Edition) revised in 2010. Allergic conjunctival disease is defined as “a conjuncti-
val inflammatory disease associated with a Type I allergy accompanied by some subjective or objective symp-
toms.” Allergic conjunctival disease is classified into allergic conjunctivitis, atopic keratoconjunctivitis, vernal
keratoconjunctivitis, and giant papillary conjunctivitis. Representative subjective symptoms include ocular itch-
ing, hyperemia, and lacrimation, whereas objective symptoms include conjunctival hyperemia, swelling, follicu-
losis, and papillae. Patients with vernal keratoconjunctivitis, which is characterized by conjunctival proliferative
changes called giant papilla accompanied by varying extents of corneal lesion, such as corneal erosion and
shield ulcer, complain of foreign body sensation, ocular pain, and photophobia. In the diagnosis of allergic con-
junctival diseases, it is required that type I allergic diathesis is present, along with subjective and objective
symptoms accompanying allergic inflammation. The diagnosis is ensured by proving a type I allergic reaction in
the conjunctiva. Given that the first-line drug for the treatment of allergic conjunctival disease is an antiallergic
eye drop, a steroid eye drop will be selected in accordance with the severity. In the treatment of vernal kerato-
conjunctivitis, an immunosuppressive eye drop will be concomitantly used with the abovementioned drugs.
KEY WORDS
allergic conjunctivitis, antiallergic eye drop, atopic keratoconjunctivitis, giant papillary conjunctivitis, vernal kera-
toconjunctivitis
1Department of Ophthalmology, Tokyo Women’s Medical Univer- Yamaguchi, 8Department of Ophthalmology, Tokyo Dental Col-
sity, School of Medicine, 3Department of Ophthalmology, Juntendo lege, Ichikawa General Hospital, Chiba, 10Nakagawa Eye Clinic,
University School of Medicine, 9Division of Ophthalmology, De- Osaka, 14Department of Ophthalmology, Kochi Medical School,
partment of Visual Sciences, Nihon University, School of Medicine, Kochi and 15Department of Ophthalmology, Tsurumi University
12Ryogoku Eye Clinic, 13Department of Ophthalmology, Keio Uni- Dental Hospital, Kanagawa, Japan.
versity School of Medicine, Tokyo, 2Department of Ophthalmology, Correspondence: Etsuko Takamura, MD, Department of Ophthal-
Fukuoka University, School of Medicine, Fukuoka, 4Department of mology, Tokyo Women’s Medical University, School of Medicine,
Ocular Inflammation and Immunology, 11Department of Ophthal- 8−1 Kawada-cho, Shinjuku-ku, Tokyo 162−8666, Japan.
mology, Hokkaido University Graduate School of Medicine, Hok- Email: takamura@oph.twmu.ac.jp
kaido, 5Department of Ophthalmology, Ehime University School of Received 28 January 2010.
Medicine, 6Okamoto Eye Clinic, Ehime, 7Kumagai Eye Clinic, !2011 Japanese Society of Allergology
Allergic conjunctival
diseases (ACD)
Fig. 1 Classification of ACD. ACD is classified as follows: (i) AC without proliferative change, (ii) AKC compli-
cated with atopic dermatitis, (iii) VKC with proliferative changes, and (iv) GPC induced by irritation of a foreign
body. Allergic conjunctivitis are subdivided into SAC and PAC according to the period of onset of the symptoms.
Fig. 2 Upper palpebral conjunctival findings in AC. Fig. 3 Upper palpebral conjunctival findings in AKC.
Mild hyperemia and edema are present. Hyperemia, opacity, and sub-conjunctival fibrosis are
present.
Number of patients
corrected by population 0.7
(ratio that the level at the
1,500 age of 10 is made 1)
0.6
0.5
1,000 0.4
0.3
500 0.2
0.1
0 0
1 10 20 30 40 50 60 70
-
Fig. 4 Upper palpebral conjunctival findings in VKC. 9 19 29 39 49 59 69
Conjunctival hyperemia, conjunctival edema, eye dis- Ages
charge, formation of giant papillae are present.
Fig. 6 Age distribution of patients with allergic conjuncti-
val diseases. The number of patients with allergic conjuncti-
val diseases who contacted the facilities was maximum at
the age of 10 and the number decreased with aging. The
peak incidence of each disease was also at the age of 10
and the incidence decreased with aging. (Incidence is cal-
culated by dividing the number of treated patients in each
age group by the entire population of the same age group in
Japan. The incidence at the age of 10 is made 1 and the re-
sult is expressed as ratio.) Adapted from reference 1.
3. PATHOPHYSIOLOGY
Fig. 5 Upper palpebral conjunctival findings in GPC.
3.1. NETWORK OF VARIOUS IMMUNE SYSTEM
Hyperemia and dome-like giant papillae are present.
CELLS AND KERATOCONJUNCTIVAL RESI-
DENT CELLS
conjunctival diseases in the entire population is esti- The pathological conditions of ACD with lesions in
mated to be about 15-20%. the conjunctiva is assumed to be caused by interac-
A research group on allergic ocular disease of the tions between various immune system cells and resi-
Japan Ophthalmologists Association conducted epide- dent cells, which are mediated by physiologically ac-
miologic surveys of all patients with allergic conjunc- tive substances (e.g. histamine and leukotriene), cy-
tival diseases that were treated at 28 facilities (7 uni- tokines, and chemokines.
versity attached hospitals, 5 general hospitals, and 16
ophthalmic hospitals and clinics) all over Japan dur- 3.2. EOSINOPHILS AND CYTOTOXIC PROTEINS
ing the period from January 1, 1993 to December 31, Eosinophils are the main effector cells in ACD. Vari-
1995. They found that female patients with SAC or ous cytotoxic proteins released from eosinophils infil-
PAC outnumbered male patients by 2 : 1, whereas trating locally into the conjunctiva are thought to
male patients with VKC outnumbered female patients cause keratoconjunctival disorders such as severe
by 2 : 1. The number of patients with ACD was maxi- AKC and VKC (Fig. 7).
mum at the age of 10 and the incidence decreased
with aging (Fig. 6). The main subjective symptoms 3.3. HELPER T AND B CELLS AND CYTOKINES
were an ocular itching, ocular hyperemia, eye dis- An immunological feature of AKC and VKC is the in-
charge, and a foreign body sensation in each disease filtration of CD4+ helper T cells (Th) and IgE-
type. In SAC, symptoms of allergic rhinitis such as producing B cells into the conjunctiva. In normal tu-
sneezing, rhinorrhea, nasal blockade were found in nica propia conjunctivae, there are resident CD4+ T
many cases. cells and CD8+ T cells.2,3 Since T cell clones infiltrate
into the conjunctiva in VKC patients and produce Th2
cytokines such as IL-4,4 which is detected in high
concentrations in the lacrimal fluid of VKC patients,5
CCR4 CCR3
Cornea Keratocyte
it appears that Th2 cells and Th2 cytokines predomi- 4.2. INSTILLATION PROVOCATION TEST
nate in VKC. On the other hand, it is reported that in When an antigen can be presumed by skin test or se-
the conjunctivae of AKC patients, Th1 and Th2 may rum antigen specific IgE antibody measurements,
be competitive.6 It is also speculated that keratocon- this test confirms the presence of conjunctivitis by in-
junctival resident cells may be involved in the etiol- stillation of a solution of the known antigen. If itching
ogy of ACD by cytokine-stimulated production of or hyperemia follows, the case is evaluated as being
chemokines such as eotaxin7,8 and TARC,9 which positive.
cause eosinophil and Th2 cell migrations from the
circulation respectively (Fig. 7). 4.3. TOTAL IgE ANTIBODY MEASUREMENT IN
LACRIMAL FLUID
4. TEST METHODS A kit is commercially available to measure the level of
The objective of tests is to prove a type I allergic reac- total IgE antibody in lacrimal fluid using an immuno-
tion in the conjunctiva and in the whole body. Clinical chromatography.11
test methods for proving type I allergic reactions in
the conjunctiva include the identification of eosino- 5. THE CLINICAL FEATURE AND EVALU-
phils in the conjunctiva, instillation provocation test, ATION CRITERIA
and total IgE antibody measurements in lacrimal 5.1. SUBJECTIVE SYMPTOMS
fluid. Systemic allergy tests detect antigen specific Representative subjective symptoms for ACD are
IgE antibodies in the skin and serum. itching, foreign body sensation, and eye discharge.
Itching is the most characteristic symptoms in
4.1. IDENTIFICATION OF EOSINOPHILS IN THE ACD, but some patients complain of a foreign body
CONJUNCTIVA sensation instead. The foreign body sensation is fre-
Eye discharge or ocular secretions collected using quently present in ACD. Aside from cases where
spatulas and tweezers, are smeared onto glass slides, slight itching is felt as a foreign body sensation, it is
then stained by Hansel or Giemsa staining methods, very likely that when many conjunctival papillae
and observed under an optical microscope.10 sweep the cornea at the time of blinking, a foreign
body sensation may occur. In ACD lymphocytes and
eosinophils account for the majority of inflammatory
cells, while neutrophils are few, serous and mucous sels is the most frequent conjunctival finding. Con-
discharge is often present, and the nature of the dis- junctival swelling is a finding that is induced by circu-
charge differs from the purulent discharge associated latory failure of the palpebral conjunctival vessels and
with bacterial conjunctivitis and viscous and serous lymphatic vessels. And in many cases, conjunctival
discharges found in viral conjunctivitis. opacity is accompanied. A conjunctival follicle is a
lymphoid follicle seen under the lower palpebral con-
5.2. OBJECTIVE SYMPTOMS junctival epithelium. This finding can be discrimi-
Conjunctival hyperemia with dilated conjunctival ves- nated from papillae by the condition of a smooth
dome-like prominence, which is surrounded by ves- 5.3. CLINICAL EVALUATION CRITERIA OF OB-
sels. Conjunctival papillae is originated from epithe- JECTIVE SYMPTOMS
lial proliferation in response to inflammation, in Major objective symptoms in each site of the palpe-
which the epithelium itself is hypertrophic. A vascu- bral conjunctiva, bulbar conjunctiva, limbal conjunc-
lar network is present from the center of the promi- tiva, and cornea were graded for severity and the
nence, although this network is seen at the upper clinical evaluation criteria were made12 Table 1.
palpebral conjunctival fornix physiologically. Papillae
of 1 mm or more in diameter, called giant papillae, 5.3.1. Palpebral Conjunctiva
are fibrous proliferative tissues found typically in The items evaluated in palpebral conjunctival findings
VKC and GPC, and a large number of inflammatory are hyperemia, swelling, follicles, papillae, and giant
cells such as lymphocytes, mast cells, and eosino- papillae. The criteria in each item are the density of
phils are observed under the epithelium. Conjunctival dilated blood vessels for hyperemia (Fig. 8), the scale
edema is caused by leakage of plasma components and the presence or absence of opacity for swelling
from the vessels. Horner-Trantas dots found at the (Fig. 9), the number of follicles in either side inferior
limbal region are small prominences induced by de- palpebral conjunctiva where more follicles are ob-
generation of proliferated conjunctival epithelium, in served than in the other side for follicle (Fig. 10). Pa-
which congregated eosinophils may be present. Cor- pillae are evaluated according to their diameter (Fig.
neal complications in severe cases include superficial 11). In case with papillae of 1 mm or more in diame-
punctate keratitis, which is a partial defect of the cor- ter, it is regarded as giant papillae (Fig. 12), which
neal epithelium, exfoliated superficial punctate kerati- are evaluated according to the prominence range. In
tis, and shield ulcer (shield-shape ulcer), which is a VKC, the papillar findings are also graded as severe.
prolonged corneal epithelial defect.
5.3.2. Bulbar Conjunctiva
The bulbar conjunctiva is evaluated according to hy-
peremia and chemosis. Since pathologic conditions sence of defective epithelium was not included in the
are characterized by marked hyperemia (Fig. 13), the grading evaluation.
grade of ”severe” hyperemia is defined as entire vas-
cular dilation. Chemosis is evaluated according to its 6. DIAGNOSIS AND DIFFERENTIAL DIAG-
shape (Fig. 14). NOSIS
In the diagnosis of allergic conjunctival diseases, it is
5.3.3. Limbal Conjunctiva required that type I allergic diathesis is present,
The Horner-Trantas dots is evaluated according to along with subjective and objective symptoms accom-
the number of the dots seen over the entire limbal re- panying allergic inflammation. The diagnosis is en-
gion (Fig. 15), and the swelling is evaluated accord- sured by proving a type I allergic reaction in the con-
ing to the range of the salmon pink swelling observed junctiva (Table 2).
at the scleral side of the limbus (Fig. 16).
6.1. CLINICAL SYMPTOMS (A)
5.3.4. Cornea (Fig. 17, 18) Frequent subjective symptoms are ocular itching, hy-
The severity of the corneal epithelial defect is used as peremia, eye discharge, foreign body sensation, ocu-
evaluation criteria. It is assumed in corneal disorders lar pain, and photophobia. The ocular itching is the
that superficial punctate keratitis is mildest and exfo- most common among all inflammatory symptoms ac-
liated superficial punctate keratitis is the next grade, companying type I allergic reactions, and is important
and corneal erosion and shield ulcer follow in sever- as a basis for diagnosis.
ity. Degenerated epithelium and mucin are deposited Other important symptoms are hyperemia, eye dis-
on the surface of the cornea and are observed as cor- charge, and lacrimation, although those symptoms
neal plaque when corneal epithelium disorder per- are not specific for allergic conjunctival diseases. For-
sists. Because the condition may persist even after eign body sensations, ocular pain, and photophobia
the inflammation is alleviated, the presence or ab- are symptoms accompanying corneal lesions and in-
Table 2 Diagnostic criteria
Clinical diagnosis (A only) Clinical symptoms specific for allergic conjunctival diseases are present.
In addition to the clinical diagnosis, positive results for serum antigen specific IgE an-
Quasi-definitive diagnosis (A + B)
tibody or skin reaction with presumed antigens.
In addition to the clinical diagnosis, or quasi-definitive diagnosis, a positive result for
Definitive diagnosis (A + B + C, A + C)
eosinophils in the conjunctival smear.
A: Clinical symptoms are present. B: Type I allergic diathesis (systemic and local diathesis) are present. C: Type I allergic reaction in the
conjunctiva is present.
are lacking, clinical diagnosis can be difficult in some proliferative lesions in the conjunctiva. The prolifera-
cases, especially in elderly cases. Since the positive tive lesion has giant papillae at the upper palpebral
rate of eosinophils in the conjunctival smear is low, conjunctiva, limbal proliferation (limbal gelatinous
repetitive testing becomes necessary for the proof in hyperplasia and Horner-Trantas dots), and corneal le-
some cases. sions at high rates and easily becomes severe. Char-
acteristic corneal lesions include exfoliated superfi-
6.4.3. Atopic Keratoconjunctivitis (AKC) cial punctate keratitis, shield ulcer (shield-shape ul-
In AKC, the atopic dermatitis is complicated with fa- cer), and corneal plaque. Clinical diagnosis is easy
cial lesions and conjunctivitis is perennially chronic because the symptoms are characteristic. Major
with ocular itching, eye discharge, papillary hyperpla- single-causative antigens are house-dust-mite, and
sia, and corneal lesions. Proliferative lesions such as the reaction with multiple kinds of antigens such as
giant papillae and limbal lesions are present in some pollens and animal scurf occurs frequently. Increased
cases. Long-term chronic inflammation may result in total IgE antibodies in serum and lacrimal fluid and
fornix foreshortening and symblepharon. Increased positive results for serum antigen specific IgE anti-
total IgE antibodies in serum and lacrimal fluid and body are detected at high rates. In addition, a high
positive results of the serum antigen specific IgE anti- positive rate of eosinophils in the conjunctival smear
body are found at high rates. is found. Consequently, the definitive diagnosis is
easy.
6.4.4. Vernal Keratoconjunctivitis (VKC)
VKC is a severe allergic conjunctival disease with
6.4.5. Giant Papillary Conjunctivitis (GPC) 7.2. SELF CARE FOR ALLERGIC CONJUNCTIVI-
In cases of contact lenses, ocular prosthesis, or surgi- TIS
cal sutures, clinical diagnosis of GPC is made when 7.2.1. Effect of Glasses for Prevention of Pollens
ocular itching, foreign body sensations, and eye dis- During pollen-flying period, goggle-type glasses are
charge are present and conjunctival hyperemia, con- recommended to carry out daily activities such as rid-
junctival edema, and papillary hyperplasia are found. ing a bicycle and having a stroll with a dog, although
GPC induced by contact lenses is called contact lens even glasses themselves can reduce the amount of
related papillary conjunctivitis. Giant papillary con- pollen flying into the ocular surface.
junctivitis represents the most severe cases, which
present with giant papillae of 1 mm or larger in di- 7.2.2. Contact Lens Insertion
ameter. The involvement of type I allergy is unknown During the pollen-flying period, it is useful to stop in-
in some cases and positive results for serum antigen serting contact lenses as much as possible, changing
specific IgE antibody are not frequent. A positive rate to glasses to avoid antigens.
of eosinophils in GPC is rarer than that in other aller-
gic conjunctival diseases. 7.2.3. Eye Washing by Artificial Tear
Antigens flying into the eye surface can be washed
6.5. DIFFERENTIAL DIAGNOSIS out by several drops of artificial tear. Because ordi-
Infectious conjunctivitis such as viral, bacterial Chla- nary artificial tear contain preservatives, when instilla-
mydia, non-inflammatory conjunctival folliculosis, and tion is repeated 4 or more times, an artificial tear
dry eye are considered as differential diagnosis. without preservatives is recommended for safety.
Since tap water reduces the stability of the layer of
7. PROPHYLAXIS: SELF-CARE tears, frequent use of water for washing eyes should
7.1. AVOIDANCE AND ELIMINATION METHODS be avoided. Cup-type eye washing tools are not rec-
BY TYPES OF ANTIGENS ommended because skin blurs around the eyes and
Perennial avoidance and elimination of antigens can antigens attaching to the skin touch the ocular sur-
be achieved by arranging the patient’s daily living en- face.
vironment, especially their indoor environment. In
contrast, the avoidance of pollen antigens is con- 8. TREATMENT: MEDICAL CARE
ducted mainly during the pollen-flying period and it is 8.1. FUNDAMENTALS OF TREATMENT
necessary to take measures so that the daily activities Drug treatment is the preferred treatment for allergic
of the patient will not be prevented by exposure to conjunctival diseases. The first option is antiallergic
pollens. eye drops, which are the basic treatment for allergic
conjunctivitis, followed by the differential use of ster-
oid eye drops as necessary according to the severity.
For severe ACDs (AKC andVKC), additional use of
immunosuppressive eye drops, steroid oral medi-
Prednisolone ○
cines, sub-tarsal conjunctival steroid injection and regularly in children because the incidence of ele-
surgical treatment such as papillary resection should vated intraocular pressure is high.14
be considered.
8.3.2. Oral Medicines
8.2. ANTIALLERGIC EYE DROPS (Table 3) Medicines are used for pediatric and other patients
Mast cell stabilizer inhibit the degranulation of mast for whom sub-tarsal conjunctival injection is difficult
cells and suppress release of mediators (e.g. hista- and for patients with corneal epithelial defect. The
mine, leukotriene, thromboxane A2), consequently, standard administration period is 1-2 weeks in consid-
the early phase reaction to type I allergy is inhibited, eration of its side effects. It is necessary to treat pa-
and conjunctival local infiltration of inflammatory tients with caution for its systemic side effects in co-
cells is curtailed, resulting in a reduction of the late operation with internists and pediatricians.
phase reaction. Histamine H1 receptor antagonists
block histamine H1 receptors, representative media- 8.3.3. Eye Ointments (Table 5)
tors released through the degranulation of mast cells, When a sufficient effect is not obtained by antiallergic
which results in suppression of hyperemia and ocular eye drops only or steroid eye drops cannot be used,
itching. ointments are used. Ointments can be applied before
going to sleep to realize the effect while sleeping. The
8.3. STEROIDS same cautions as those in using steroid eye drops are
8.3.1. Eye Drops (Table 4) necessary.
When a sufficient effect cannot be obtained by antial-
lergic eye drops only, eye drops with a titer corre- 8.3.4. Sub-Tarsal Conjunctival Injection of Ster-
sponding to the severity of inflammation are com- oid Suspension
bined. Local side effects include elevation of intraocu- Triamcinolone acetonide or betamethasone suspen-
lar pressure,13 induction of infection, and cataracts. It sion is injected to the sub-tarsal conjunctiva of the up-
is necessary to measure the intraocular pressure per eyelid in intractable or severe cases. With caution
Surgical
treatment
Steroid eye drops (high titer)
Steroid oral medication or sub-tarsal
conjunctival steroid injection
Severe
Steroid eye drops (low titer) or steroid eye ointments
Moderate
Immunosuppressive eye drops
Mild
Antiallergic eye drops
for the elevation of intraocular pressure, it is desir- 8.6.2. Atopic Keratoconjunctivitis (AKC)
able to avoid repeated use or the application to chil- When antiallergic eye drops alone are not sufficiently
dren aged less than 10 years. effective, a steroid eye drop is combined. At the same
time, it is necessary to treat atopic blepharitis ac-
8.4. IMMUNOSUPPRESSIVE EYE DROPS (Table tively. When a steroid oral medicine is prescribed,
6) the treatment should be conducted in cooperation
At present, 2 kinds of immunosuppressive eye drops with an internist and a dermatologist.
(cyclosporin and tacrolimus) have been approved as
treatment drugs for vernal keratoconjunctivitis. Im- 8.6.3. Vernal Keratoconjunctivitis (VKC)
munosuppressive eye drops are expected to have For moderate or more severe cases such that antial-
equivalent or better effects than steroid eye drops. lergic eye drops alone are not sufficiently effective, an
Cyclosporin enables the gradual reduction of the immunosuppressive eye drop is added. For severe
doses of steroid eye drops by combined administra- cases when improvement cannot be achieved by 2
tion with antiallergic eye drops and steroid eye drugs, a steroid eye drop is added, and depending on
drops.15 Tacrolimus itself also has effects on steroid- the symptoms, a steroid oral medicine and sub-tarsal
resistant severe cases.16 conjunctival steroid injection or surgical treatment
should be attempted. When the symptoms are allevi-
8.5. SURGICAL TREATMENT ated, the steroid eye drop should be changed to one
For cases where symptoms are not alleviated by drug with a lower titer or the number of the instillation
treatment and conjunctival papillary hyperplasia pro- should be gradually decreased, eventually stopping
gresses to cause worsened corneal epithelium disor- administration. Then, the treatment is conducted
der, a tarsal conjunctival resection, including the pa- with an antiallergic eye drop and an immunosuppres-
pillae may be performed. While the treatment effect sive eye drop, and if the remission period becomes
is immediate, it may recur in some cases. Although long, control is continued with the antiallergic eye
corneal plaques may be removed by surgical curet- drop only (Fig. 20).
tage, the treatment is performed only when the pa-
thologic condition has been alleviated. 8.6.4. Giant Papillary Conjunctivitis (GPC)
When a contact lens has a causative, the use of the
8.6. SELECTION OF TREATMENT METHODS contact lens is stopped as a rule, for the purpose of
8.6.1. Allergic Conjunctivitis avoiding mechanical irritation and antigens. The first
The first option is antiallergic eye drops. A mast cell option is an antiallergic eye drop and in severe cases,
stabilizer and a histamine H1 receptor antagonist can a steroid eye drop is added. Because there have been
be combined. During a period with severe symptoms, frequent problems in the care of lenses, it is neces-
a steroid eye drop is combined. In seasonal allergic sary to instruct patients in rub washing and changing
conjunctivitis, when the administration of an antialler- of care tools.
gic eye drop is started about 2 weeks prior to the pre-
dicted day of the start of flying pollen or at the time REFERENCES
when little symptoms appear, so that the symptoms 1. Japanese Ocular Allergology Society. [Guidelines for the
decrease during the peak time of flying pollen.17,18 clinical management of allergic conjunctival disease (2nd
edition)]. Nippon Ganka Gakkai Zasshi [J Jpn Ophthalmol